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Biodegradable Scaffolds
CRT-600
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Scaffolds (Absorb™) and Xience™ Stents - A Comparison Based on Optical Coherence
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Background and Aim: In addition to lesion characteristics, post-stenting.
Results: Depend on characteristics of the stent and on the inﬂating pressure of the stent
balloon or post-dilation balloon. The biodegradable ABSORB scaffold has a greater
ﬂexibility (lower maximum compressive load required to deﬂect the device) compared to
the XIENCE stent but due to its fragility the inﬂating pressure is limited and suitable
lesions have to be well prepared. Aim of this study was to assess the incidence of mal-
apposed stent-struts after ABSORB implantation as well as the frequency of stent-
underexpansion and edge dissections compared to the XIENCE stent.
Methods: 23 patients after elective implantation of an ABSORB scaffold (n¼30)
were matched with 26 patients after implantation of a XIENCE stent (n¼30) ac-
cording to gender, age, stent-diameter and length. Stenting results were assessed using
Optical Coherence Tomography (OCT) and compared between groups.
Results: Pre-dilation was more frequently done in the ABSORB group (n¼28 vs.
n¼19, p¼0.005). Inﬂation time was longer in ABSORB group (44.4314.21 vs.
27.93 9.42sec, p<0.001) and the inﬂation pressure of the stent-balloon was lower
(11.432.85 vs. 13.572.84atm, p¼0.005). No differences were found in frequency of
NC-balloon post-dilation as well as in its inﬂating pressure. Post-implantation, less
ABSORB-struts were malapposed (10.8322.75 vs. 40.9358.50, p¼0.011),
incidence of underexpansion was similar and edge dissections occurred in trend more
frequently in the XIENCE group (n¼6 vs. n¼12, p¼0.079).
Conclusion: OCT assessment post implantation showed less adverse results con-
cerning the ABSORB scaffold compared to the XIENCE stent.
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Background: Bioresorbable vascular scaffolds (BVS) are a novel innovation in
treatment of coronary artery lesions. Initial angiographic procedure results seem to be
satisfying, but data concerning optimal scaffold expansion and its radial force are rare,
so our aim was to assess intravascular conformability as a hint for radial strength.
Methods: Post-implantation, Optical Coherence Tomography (OCT) images of 40
ABSORB scaffolds were evaluated and compared to 40 XIENCE stents. Pro-
cedure characteristics were collected and area, where deformation per visual assessment
was most pronounced was identiﬁed and minimal-, maximal-diameter and diameter-
ratio were calculated and compared between groups.
Results: Patients receiving ABSORB scaffolds were younger than those with
XIENCE stents (54.011.2 versus 61.711.4, p¼0.012), the remaining baseline
characteristics were comparable between groups. Lesions treated with scaffolds were
predilated more frequently (n¼34 versus n¼23, p¼0.006) and inﬂation time waslonger than in XIENCE stents (44.212.8 versus 25.68.4 seconds, p<0.001).
Maximal inﬂation pressure as well as incidence of postdilation with a Non-Compliant
(NC) balloon was similar in both devices. Furthermore, the extent of coronary calci-
ﬁcation was similar and reference vessel diameters, proximal and distal, were also
comparable. Diameter-ratio between maximal- and minimal-diameter was signiﬁ-
cantly higher in the ABSORB group (1.460.20 versus 1.320.19, p¼0.004).
Conclusion: Bioresorbable scaffolds are characterized by its greater conformability
than comparable Drug Eluting Stents (DES) and therefore, with the optimal inﬂation
strategy, struts are well opposed to the vessel wall. Nevertheless, BVS show a less
complete radial expansion compared to XIENCE stents.
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Background: The Chocolate Balloon Catheter exhibits a nitinol constraining
structure covering the external aspect of the balloon that distributes radial force to the
arterial surface more evenly than conventional angioplasty balloon constructs. The
safety and efﬁcacy of a paclitaxel (PTX)-coated Chocolate Balloon Catheter was
investigated in a stent overstretch model.
Methods: Twenty six farm swine were studied at a 30 days. Angioplasty of coronary
arteries was performed with a 16% overstretch and 60s inﬂation. Devices were coated
with 3ug/mm2 (for single inﬂation, nominal dose) or 6ug/mm2 (two consecutive in-
ﬂations, high dose) paclitaxel using a proprietary carrier. Control devices included the
SeQuentPlease (3ug/mm2 PTX, B. Braun, positive control) and a standard balloon
(Maverick2, Boston Scientiﬁc, negative control). All devices were 3.5x20mm.
Following angioplasty a stent (Omega Ous, Boston Scientiﬁc, 3.5x16mm) was placed in
the treatment location to stimulate neointimal response. Target arteries were evaluated
angiographically pre and post treatment, by histology and histomorphometrically.
Myocardial function was assessed using left ventricular ejection fractions and ECG.
Results: There were no device failures or device-related animal morbidity or mor-
tality. No target-site thrombi or thromboemboli were observed in any of the paclitaxel
treatment groups. There were no signiﬁcant changes in myocardial function or his-
tology attributable to PTX treatment. Late lumen loss was more than double for the
uncoated balloon treatment group compared to the PTX treated groups. Intimal
suppression was comparable between the Chocolate and SeQuentPlease treatment
groups. Injury and inﬂammation scores were equivalent across all treatment groups;
although there was a slight increase in the injury score for the high dose group likely
due to the double inﬂations.
Conclusion: In a preclinical model of intimal thickening, the PTX-coated Chocolate
Balloon Catheter demonstrated signiﬁcant intimal suppression relative to uncoated
balloon treatments and a favorable safety proﬁle.
